Previous 10 | Next 10 |
SAN JOSE, Calif. , Sept. 9, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended July 31, 2019 . Recent H...
BioPharmX Corporation ( BPMX ) is a pharmaceutical company that announced on Monday 25 June that it had positive topline results from its Phase 2b trial of BPX-04 for Papulopustular Rosacea (BPX-04 being a topical gel, and papulopustular rosacea being a skin disorder causing redness, swellin...
Small biotech company BioPharmX Corp (NYSE:BPMX) has been on a tear in Tuesday’s trading session, and BPMX stock rose by as much as 30% on the back of highly positive news about its topical minocycline gel BPX-04. Highly Positive Results According to the announcement made today, ...
Nano cao BioPharmX (NYSEMKT: BPMX ) is up 60% premarket on robust volume in response to positive results from a Phase 2b clinical trial, PRISM , evaluating topical minocycline gel BPX-04 in patients with moderate-to-severe papulopustular rosacea , a skin disorder akin to acne...
SAN JOSE, Calif. , June 25, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced positive results from its Phase 2b clinical trial of BPX-04 1 , a novel to...
BioPharmX (NYSEMKT: BPMX ): Q1 Non-GAAP EPS of -$0.36; GAAP EPS of -$0.38 misses by $0.10 . More news on: BioPharmX Corporation, Earnings news and commentary, , Read more ...
SAN JOSE, Calif. , June 11, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended April 30, 2019. Recent...
BioPharmX ( BPMX -6.2% ) reports that the last patient in its Phase 2b clinical trial evaluating topical gel BPX-04 for the treatment of papulopustular rosacea has completed the last clinical visit. More news on: BioPharmX Corporation, Healthcare stocks news, Read more ...
SAN JOSE, Calif. , May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical trial of BPX-04 1 ...
BioPharmX (NYSEMKT: BPMX ) -3% . More news on: BioPharmX Corporation, STMicroelectronics N.V., UP Fintech Holding Limited, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
BioPharmX Corporation. Common Company Name:
BPMX Stock Symbol:
NYSE Market:
CAMPBELL, Calif. , May 15, 2020 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX" or the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that, in anticipation of closing its merger with Ti...
Are These On Your List Of Penny Stocks To Watch? If you’re looking for some penny stocks to watch today, it’s important to understand certain trends. For instance, countless stocks under $5 have made huge moves this year thanks to COVID-19. However, not all penny stocks deali...
CAMPBELL, Calif. , May 13, 2020 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") today announced that all proposals related to its proposed merger with Timber Pharmaceuticals LLC ("Timber") were approved by BioPharmX's stockholders at a special meeting he...